RENOVION
Renovion is a clinical-stage biopharmaceutical company developing ARINA-1, a novel nebulized mucolytic therapy targeting mucus, inflammation, and infection in lung transplant, non-CF bronchiectasis, and chronic bronchitis patients.
- Company typePrivate
- Founded2013
- HeadquartersChapel Hill, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What RENOVION does
Renovion, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2013 and headquartered in Chapel Hill, North Carolina. The company develops ARINA-1, a single novel nebulized therapy consisting of a sterile buffered ascorbic acid and glutathione solution delivered to the airways via a customized PARI mesh nebulizer. ARINA-1 is positioned as a next-generation mucolytic that replenishes ions depleted under chronic inflammatory conditions; the mechanism improves mucociliary clearance, decreases damaging inflammation, and provides direct antibacterial activity without bacterial resistance concerns, functioning independently of CFTR. Renovion is advancing ARINA-1 through Phase 3 (BOS prevention in lung transplant) and Phase 2 (Non-CF Bronchiectasis) clinical programs across sites in the United States, with chronic bronchitis as a third targeted indication.
The business model is a standard pre-commercial pharmaceutical model: Renovion is pre-revenue, generates no product sales today, and is funded almost entirely through equity (approximately $29.4M disclosed across rounds, including a ~$15M raise in 2023 from 24 investors, and prior rounds totaling roughly $14M between 2018–2020). Revenue, when generated, will come from product sales of ARINA-1 upon FDA approval, supported by Orphan Drug exclusivity (lung transplant) and Fast Track designation. The IP estate — composition-of-matter, method-of-use, and NCE claims across 5 patent families — was originally licensed from UNC-Chapel Hill, where the foundational research was conducted by David Henke and Roland Arnold.
Customer concentration in the commercial sense is not yet relevant because no products are sold. Today, Renovion's "users" are clinical trial participants — approximately 40 patients in the Phase 2 CLIMB study (NCFBE) and an expected ~100 across 15 sites in the Phase 3 ALOFT study (lung transplant). Patient recruitment is conducted in partnership with the COPD Foundation and Lung Transplant Foundation. Operational scale is intentionally lean: 1–10 employees, supported by an outsourced clinical-trial site model (with 9–15 US sites per program), contract manufacturing, and a deep partnership network across patient advocacy, academic research, and device delivery.
RENOVION firmographics
Firmographics- Name
- RENOVION
- Legal name
- Renovion, Inc.
- Website
- https://renovion.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Renovion is a clinical-stage biopharmaceutical company developing ARINA-1, a novel nebulized mucolytic therapy targeting mucus, inflammation, and infection in lung transplant, non-CF bronchiectasis, and chronic bronchitis patients.
- Ownership category
- akta.pro rank
Where RENOVION is headquartered
LocationHeadquarters
- HQ city
- Chapel Hill
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
RENOVION business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Revenue: Pre-revenue clinical-stage company. ARINA-1 is in Phase 2/3 clinical trials for multiple indications. Revenue will be generated through product sales upon FDA approval. The company is developing a proprietary nebulized therapy targeting mucus-related lung diseases with no approved treatment options currently available.
Distribution channels1 record
Marketing channels7 records
RENOVION product offering
Product offeringCore offering
Renovion is developing ARINA-1, a novel nebulized therapy consisting of a sterile buffered ascorbic acid/glutathione solution delivered directly to the lungs via a specialized PARI mesh nebulizer. The therapy is being advanced through Phase 2 and Phase 3 clinical trials for three indications: prevention of bronchiolitis obliterans syndrome (BOS) in bilateral lung transplant patients, treatment of non-cystic fibrosis bronchiectasis (NCFBE), and chronic bronchitis. ARINA-1 targets the cycle of mucus, inflammation, and infection by clearing mucus, reducing damaging inflammation, and providing antibacterial properties.
Product overview
Renovion is a clinical-stage pharmaceutical company developing ARINA-1, a single novel nebulized therapy for treating chronic inflammatory lung diseases. ARINA-1 is a sterile buffered ascorbic acid/glutathione solution delivered via a specialized PARI mesh nebulizer. The therapy targets the cycle of mucus, inflammation, and infection in conditions including lung transplant (BOS prevention), non-CF bronchiectasis (NCFBE), and chronic bronchitis. The company operates with a focused pipeline approach, advancing ARINA-1 through Phase 2 and Phase 3 clinical trials across multiple indications.
Differentiator
Problem solved
Functional benefit
Products and services
- ARINA-1 Novel nebulized therapy consisting of a sterile buffered ascorbic acid/glutathione solution delivered directly to the lungs via a specialized PARI mesh nebulizer. It clears mucus, reduces damaging inflammation, and has antibacterial properties to restore lung health in patients with chronic inflammatory lung diseases including lung transplant (BOS prevention), non-CF bronchiectasis, and chronic bronchitis.
Quantifiable outcome
- Quality of life improvement: SGRQ total score improved by -8.5 at day 28 (MCID threshold is -4), more than twice the minimal clinically important difference
- +4 more outcomes
Companies that use RENOVION
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
RENOVION technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RENOVION partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered supporting and core.
- ExploristicssupportingCollaboration using Exploristics' KerusCloud study simulation software platform to establish efficient data-driven approach to study design and protocol development. Implemented across two projects to reduce risks, costs, and duration of development programs in NCFBRE and COPD.
- COPD FoundationcoreRenovion and COPD Foundation launched a partnership to accelerate development of ARINA-1 for COPD and non-CF bronchiectasis. The partnership leverages the COPD Foundation's global partnerships and COPD360Net for patient-centered drug development. Phase 2 clinical trials planned to begin in Q1 2022.
- PARIsupportingPartnership with PARI to deliver ARINA-1 via a nebulizer developed specifically for the therapy. PARI developed a specific mesh for the nebulizer that delivers high concentrations of drug into the airway.
- Lung Transplant FoundationsupportingCollaboration for patient education and clinical trial awareness. Carolyn Durham, CSO at Renovion participated in BOS Education Day discussion with Lung Transplant Foundation.
- UNC-Chapel HillcoreRenovion was formed in 2013 to leverage a discovery at UNC-Chapel Hill. The company licensed patent rights to ARINA-1 from UNC and continues to build intellectual property around the asset. UNC researchers David Henke and Roland Arnold contributed foundational research.
- Duke UniversitysupportingPhase 1 clinical trial in patients with lung dysfunction following bilateral lung transplant conducted at Duke University.
- UAB Gregory Fleming James Cystic Fibrosis Research CentersupportingResearch collaboration with The Rowe Lab at UAB demonstrating impact of ARINA-1 on mucus transport in cystic fibrosis. Study funded in part by Cystic Fibrosis Foundation and published in American Journal of Respiratory Cell and Molecular Biology.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
RENOVION competitors and assessment
Company assessmentDirect peers
- Insmed: Insmed's lead asset brensocatib is in Phase 3 development for non-CF bronchiectasis, making it the most directly comparable competitor to Renovion in the NCFBE space with a similar mechanism focus on neutrophilic inflammation and similar clinical-stage profile.
- Savara Inc. Savara (formed via Aadi/Aerpio merger) is a small-cap respiratory biotech developing molgramostim for autoimmune PAP and NCFBE — directly comparable in scale, indication overlap, and at-home inhaled therapeutic delivery to Renovion's ARINA-1 platform.
- Liquidia Corporation: Liquidia is a small-cap respiratory biotech commercializing inhaled treprostinil (YUTREPIA) for pulmonary hypertension. Comparable as a small-cap respiratory inhaled-therapeutics company facing similar commercialization and reimbursement dynamics to Renovion's planned launch.
Emerging players
- Arcturus Therapeutics: Arcturus is developing inhaled mRNA therapies for cystic fibrosis and other respiratory diseases. Overlapping CF indication and respiratory delivery focus, though differentiated by mRNA modality vs. Renovion's small molecule.
Regional players
- Zambon: Zambon is an Italian-headquartered pharmaceutical company with a colistimethate dry powder product (Colobreathe) for chronic Pseudomonas infections in NCFBE/CF patients — overlapping indication with Renovion but focused on European markets.
Broad incumbents
- Vertex Pharmaceuticals: Vertex dominates the cystic fibrosis franchise (Trikafta/Kaftrio) and has acquired Parion Sciences for mucus-clearing epithelial sodium channel inhibitors — a direct technology-space overlap with Renovion's mucus clearance focus.
- GSK: GSK is the largest respiratory pharma (Advair/Trelegy/Nucala) and Renovion CEO Dan Copeland previously worked on Advair at GSK. GSK's established COPD/chronic bronchitis sales force and physician relationships represent the primary competitive commercial overlap.
- Boehringer Ingelheim: Boehringer Ingelheim's respiratory franchise (Spiriva, Ofev) targets COPD and progressive pulmonary diseases — overlapping target indications with Renovion's chronic bronchitis and BOS programs through a large established pharma.
- AstraZeneca: AstraZeneca has a deep respiratory portfolio (Symbicort, Fasenra, Trixeo) across COPD/asthma and is actively investing in mucus-clearing biologics — overlapping chronic respiratory disease focus and providing commercial competitive landscape for Renovion's chronic bronchitis entry.
Others
- Pulmonx Corporation: Pulmonx is a commercial-stage lung health company (Zephyr valves for COPD/emphysema) — adjacent specialty respiratory focus with comparable small-cap scale to Renovion, though addressing lung disease via interventional rather than pharmacologic means.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
RENOVION social profiles
Digital presenceRENOVION financial estimates
Financial estimateRevenue estimate
Valuation estimate
RENOVION leadership team
Management profileNumber of profiles
Profiles7 records
RENOVION funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RENOVION M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RENOVION
What does RENOVION do?
Renovion is developing ARINA-1, a novel nebulized therapy consisting of a sterile buffered ascorbic acid/glutathione solution delivered directly to the lungs via a specialized PARI mesh nebulizer. The therapy is being advanced through Phase 2 and Phase 3 clinical trials for three indications: prevention of bronchiolitis obliterans syndrome (BOS) in bilateral lung transplant patients, treatment of non-cystic fibrosis bronchiectasis (NCFBE), and chronic bronchitis. ARINA-1 targets the cycle of mucus, inflammation, and infection by clearing mucus, reducing damaging inflammation, and providing antibacterial properties.
Is RENOVION a public or private company?
RENOVION is a private company. It is classified as venture growth investor backed and is currently operating.
When was RENOVION founded?
RENOVION was founded in 2013. It employs 1 to 10 people.
Where is RENOVION based?
RENOVION is headquartered in Chapel Hill, United States, in the North America region.
How does RENOVION make money?
One revenue line is on record: pharmaceutical Product Revenue.
Who are RENOVION's main competitors?
Direct peers on record are Insmed, Savara Inc. and Liquidia Corporation. Arcturus Therapeutics is listed as an emerging player. Zambon is listed as a regional player. Broad incumbents are Vertex Pharmaceuticals, GSK, Boehringer Ingelheim and AstraZeneca. Pulmonx Corporation is listed as an others.
Does RENOVION have an API?
No public API is recorded for RENOVION.